Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Non-Current Assets (2016 - 2025)

Fate Therapeutics' Non-Current Assets history spans 14 years, with the latest figure at $110.2 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 25.91% year-over-year to $110.2 million; the TTM value through Dec 2025 reached $524.3 million, down 27.01%, while the annual FY2025 figure was $110.2 million, 25.91% down from the prior year.
  • Non-Current Assets reached $110.2 million in Q4 2025 per FATE's latest filing, down from $122.4 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $302.4 million in Q2 2021 to a low of $110.2 million in Q4 2025.
  • Average Non-Current Assets over 5 years is $199.5 million, with a median of $192.5 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: soared 166.74% in 2021, then crashed 33.71% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $288.0 million in 2021, then decreased by 29.36% to $203.5 million in 2022, then fell by 14.16% to $174.7 million in 2023, then fell by 14.82% to $148.8 million in 2024, then decreased by 25.91% to $110.2 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Non-Current Assets are $110.2 million (Q4 2025), $122.4 million (Q3 2025), and $141.2 million (Q2 2025).